September 6, 2022
Obsidian Therapeutics to Participate in Citi’s 17th Annual BioPharma Conference 2022
CAMBRIDGE, Mass., September 6, 2022 – Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, today announced that management will attend Citi’s 17th Annual BioPharma Conference 2022. The event will be hosted in-person in Boston from September 7-8, 2022.
Jan ter Meulen, Ph.D., Chief Scientific Officer of Obsidian, will be participating in a panel on cell therapy on September 7, at 3:30 p.m. ET.
Obsidian will also take part in 1×1 investor meetings during the event.
OBX-115 is a novel engineered tumor-infiltrating lymphocyte (TIL) therapy armed with regulated membrane-bound IL15 that is designed to remove the need for concomitant IL2 therapy, a toxic and costly requirement for conventional TILs. OBX-115 preclinical data have demonstrated enhanced TIL persistence, potency and improved tumor control compared to unengineered TILs, which is anticipated to improve clinical outcomes in patients suffering from different types of solid tumors. FDA granted IND clearance for OBX-115 in July 2022.
About Obsidian Therapeutics
Obsidian Therapeutics, Inc. is a clinical biotechnology company pioneering engineered cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. Obsidian’s proprietary cytoDRiVE® technology provides a way to precisely control the timing and level of protein function by using FDA approved small molecules. Obsidian is headquartered in Cambridge, MA. The Company has collaborations with Bristol Myers Squibb and Vertex Pharmaceuticals. For more information, please visit www.obsidiantx.com and follow us on LinkedIn and Twitter.
Russo Partners, LLC